Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended

MT Newswires Live

2025/01/10

Seres Therapeutics (MCRB) said results from a phase 1b trial of SER-155 in people undergoing allogenic stem cell transplantation showed a "positive impact on biomarkers of systemic inflammation and immune homeostasis" compared with placebo.

The results back previous data showing that SER-155 "was associated with a significant reduction in bloodstream infections," the company said Thursday in a statement.

SER-155 is a live biotherapeutic designed to prevent infections in people undergoing allogenic stem cell transplantation to treat blood cancers, Seres said.

The company also said its cash runway was extended into Q1 2026.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2502047235"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502047235\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502047235?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 01:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502047235","market":"nz","top_or_hot":-1,"title":"Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended","media":"MT Newswires Live","content":"<html><body><p> Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (MCRB) said results from a phase 1b trial of SER-155 in people undergoing allogenic stem cell transplantation showed a \"positive impact on biomarkers of systemic inflammation and immune homeostasis\" compared with placebo.</p><p>The results back previous data showing that SER-155 \"was associated with a significant reduction in bloodstream infections,\" the company said Thursday in a statement.</p><p>SER-155 is a live biotherapeutic designed to prevent infections in people undergoing allogenic stem cell transplantation to treat blood cancers, Seres said.</p><p>The company also said its cash runway was extended into Q1 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-10 01:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (MCRB) said results from a phase 1b trial of SER-155 in people undergoing allogenic stem cell transplantation showed a \"positive impact on biomarkers of systemic inflammation and immune homeostasis\" compared with placebo.</p><p>The results back previous data showing that SER-155 \"was associated with a significant reduction in bloodstream infections,\" the company said Thursday in a statement.</p><p>SER-155 is a live biotherapeutic designed to prevent infections in people undergoing allogenic stem cell transplantation to treat blood cancers, Seres said.</p><p>The company also said its cash runway was extended into Q1 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MCRB","symbol_name":"Seres Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2502047235","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502047235","pubTimestamp":1736443981,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Seres Therapeutics  said results from a phase 1b trial of SER-155 in people undergoing allogenic stem cell transplantation showed a \"positive impact on biomarkers of systemic inflammation and immune homeostasis\" compared with placebo.The results back previous data showing that SER-155 \"was associated with a significant reduction in bloodstream infections,\" the company said Thursday in a statement.SER-155 is a live biotherapeutic designed to prevent infections in people undergoing allogenic stem cell transplantation to treat blood cancers, Seres said.The company also said its cash runway was extended into Q1 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MCRB":"Seres Therapeutics, Inc.","BK4139":"生物科技","SER":"Serina Therapeutics, Inc."},"translate_title":"Seres Therapeutics报告SER-155早期试验产生“积极影响”；现金跑道延长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SER":1,"MCRB":1},"content_text":"Seres Therapeutics (MCRB) said results from a phase 1b trial of SER-155 in people undergoing allogenic stem cell transplantation showed a \"positive impact on biomarkers of systemic inflammation and immune homeostasis\" compared with placebo.The results back previous data showing that SER-155 \"was associated with a significant reduction in bloodstream infections,\" the company said Thursday in a statement.SER-155 is a live biotherapeutic designed to prevent infections in people undergoing allogenic stem cell transplantation to treat blood cancers, Seres said.The company also said its cash runway was extended into Q1 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}